Search

How Can We Help You?

Video

Quick Info:

Find a Doctor Specialties (800) 213-3284

Select Clinical Trial

Protocol Number: SWOG 1826 Hodgkin Lymphoma

Protocol Title: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 18 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.

Eligibility: Patient population age 18 years or older with newly diagnosed advanced stage Classical Hodgkin Lymphoma.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Alliance A041702 Chronic Lymphocytic Leukemia (CLL)

Protocol Title: Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients.

Eligibility: Patient population 70 years or greater that have received no treatment for confirmed Chronic Lymphocytic Leukemia (CLL).

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: ECOG EA9161

Protocol Title: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Patients with Chronic Lymphocytic Leukemia (CLL).

Eligibility: Men and women age ≥ 18 years and < 70 years of age with a diagnosis of biopsy proven CLL..

Contact Information: (910) 715-2200

Specialties
Clara McLean House
Make a Donation
News & Events